Cargando…
Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Caucasian population. METHODS: We retrospectively analyzed 178 Chinese CMML patie...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128105/ https://www.ncbi.nlm.nih.gov/pubmed/35610628 http://dx.doi.org/10.1186/s40164-022-00284-z |
_version_ | 1784712492243484672 |
---|---|
author | Nie, Yanbo Shao, Liang Zhang, Hong He, Colin K. Li, Hongyu Zou, Junyan Chen, Long Ji, Huaiyue Tan, Hao Lin, Yani Ru, Kun |
author_facet | Nie, Yanbo Shao, Liang Zhang, Hong He, Colin K. Li, Hongyu Zou, Junyan Chen, Long Ji, Huaiyue Tan, Hao Lin, Yani Ru, Kun |
author_sort | Nie, Yanbo |
collection | PubMed |
description | BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Caucasian population. METHODS: We retrospectively analyzed 178 Chinese CMML patients. The targeted next generation sequencing (NGS) was used to evaluate 114 gene variations, and the prognostic factors for OS were determined by COX regression analysis. RESULTS: The CMML patients showed a unique mutational spectrum, including TET2 (36.5%), NRAS (31.5%), ASXL1 (28.7%), SRSF2 (24.7%), and RUNX1 (21.9%). Of the 102 patients with clonal analysis, the ancestral events preferentially occurred in TET2 (18.5%), splicing factors (16.5%), RAS (14.0%), and ASXL1 (7.8%), and the subclonal genes were mainly ASXL1, TET2, and RAS. In addition, the secondary acute myeloid leukemia (sAML) transformed from CMML often had mutations in DNMT3A, ETV6, FLT3, and NPM1, while the primary AML (pAML) demonstrated more mutations in CEBPA, DNMT3A, FLT3, IDH1/2, NPM1, and WT1. It was of note that a series of clones were emerged during the progression from CMML to AML, including DNMT3A, FLT3, and NPM1. By univariate analysis, ASXL1 mutation, intermediate- and high-risk cytogenetic abnormality, CMML-specific prognostic scoring system (CPSS) stratifications (intermediate-2 and high group), and treatment options (best supportive care) predicted for worse OS. Multivariate analysis revealed a similar outcome. CONCLUSIONS: The common mutations in Chinese CMML patients included epigenetic modifiers (TET2 and ASXL1), signaling transduction pathway components (NRAS), and splicing factor (SRSF2). The CMML patients with DNMT3A, ETV6, FLT3, and NPM1 mutations tended to progress to sAML. ASXL1 mutation and therapeutic modalities were independent prognostic factors for CMML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00284-z. |
format | Online Article Text |
id | pubmed-9128105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91281052022-05-25 Mutational landscape of chronic myelomonocytic leukemia in Chinese patients Nie, Yanbo Shao, Liang Zhang, Hong He, Colin K. Li, Hongyu Zou, Junyan Chen, Long Ji, Huaiyue Tan, Hao Lin, Yani Ru, Kun Exp Hematol Oncol Research BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Caucasian population. METHODS: We retrospectively analyzed 178 Chinese CMML patients. The targeted next generation sequencing (NGS) was used to evaluate 114 gene variations, and the prognostic factors for OS were determined by COX regression analysis. RESULTS: The CMML patients showed a unique mutational spectrum, including TET2 (36.5%), NRAS (31.5%), ASXL1 (28.7%), SRSF2 (24.7%), and RUNX1 (21.9%). Of the 102 patients with clonal analysis, the ancestral events preferentially occurred in TET2 (18.5%), splicing factors (16.5%), RAS (14.0%), and ASXL1 (7.8%), and the subclonal genes were mainly ASXL1, TET2, and RAS. In addition, the secondary acute myeloid leukemia (sAML) transformed from CMML often had mutations in DNMT3A, ETV6, FLT3, and NPM1, while the primary AML (pAML) demonstrated more mutations in CEBPA, DNMT3A, FLT3, IDH1/2, NPM1, and WT1. It was of note that a series of clones were emerged during the progression from CMML to AML, including DNMT3A, FLT3, and NPM1. By univariate analysis, ASXL1 mutation, intermediate- and high-risk cytogenetic abnormality, CMML-specific prognostic scoring system (CPSS) stratifications (intermediate-2 and high group), and treatment options (best supportive care) predicted for worse OS. Multivariate analysis revealed a similar outcome. CONCLUSIONS: The common mutations in Chinese CMML patients included epigenetic modifiers (TET2 and ASXL1), signaling transduction pathway components (NRAS), and splicing factor (SRSF2). The CMML patients with DNMT3A, ETV6, FLT3, and NPM1 mutations tended to progress to sAML. ASXL1 mutation and therapeutic modalities were independent prognostic factors for CMML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00284-z. BioMed Central 2022-05-24 /pmc/articles/PMC9128105/ /pubmed/35610628 http://dx.doi.org/10.1186/s40164-022-00284-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nie, Yanbo Shao, Liang Zhang, Hong He, Colin K. Li, Hongyu Zou, Junyan Chen, Long Ji, Huaiyue Tan, Hao Lin, Yani Ru, Kun Mutational landscape of chronic myelomonocytic leukemia in Chinese patients |
title | Mutational landscape of chronic myelomonocytic leukemia in Chinese patients |
title_full | Mutational landscape of chronic myelomonocytic leukemia in Chinese patients |
title_fullStr | Mutational landscape of chronic myelomonocytic leukemia in Chinese patients |
title_full_unstemmed | Mutational landscape of chronic myelomonocytic leukemia in Chinese patients |
title_short | Mutational landscape of chronic myelomonocytic leukemia in Chinese patients |
title_sort | mutational landscape of chronic myelomonocytic leukemia in chinese patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128105/ https://www.ncbi.nlm.nih.gov/pubmed/35610628 http://dx.doi.org/10.1186/s40164-022-00284-z |
work_keys_str_mv | AT nieyanbo mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT shaoliang mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT zhanghong mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT hecolink mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT lihongyu mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT zoujunyan mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT chenlong mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT jihuaiyue mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT tanhao mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT linyani mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients AT rukun mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients |